Neuroblastoma (NB), the most frequent extracranial solid tumor of children accounting for
nearly 15% of all childhood cancer mortality, displays overexpression of antiapoptotic Bcl-2 …

Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …

Olomoucine and Roscovitine are pharmacological inhibitors of cyclin-dependent kinases
(CDK) displaying a promising profile as anticancer agents. Both compounds are effective …

To understand the mechanisms of action of (R)-roscovitine and (S)-CR8, two related
pharmacological inhibitors of cyclin-dependent kinases (CDKs), we applied a variety of ' …

The pediatric solid tumor neuroblastoma (NB) often depends on the anti-apoptotic protein,
Mcl-1, for survival through Mcl-1 sequestration of pro-apoptotic Bim. High affinity Mcl-1 …

Chemical inhibitors of cyclin-dependent kinase (CDK), like roscovitine, are promising drugs
in the context of new cancer therapies. Roscovitine and related compounds, like seliciclib …

Escape from the proper control of the cell cycle by up-regulation of cyclins or aberrant
activation of cyclin-dependent kinases (CDKs) as well as by inactivation of cellular inhibitors …

Olomoucine and Roscovitine are two ATP-competing compounds described as specific
inhibitors of cyclin-dependent kinases (CDK). Both drugs showed to induce apoptosis in SH …

Deregulation of the cell cycle commonly occurs during tumorigenesis, resulting in
unrestricted cell proliferation and independence from mitogens. Cyclin-dependent kinase …

Cyclin-dependent kinases (CDKs) and their regulators show frequent abnormalities in
tumors. Ten low molecular weight pharmacologic inhibitors of CDKs are currently in clinical …